Press Releases

Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading, diversified specialty pharmaceutical company committed to improving the lives of people living with serious medical conditions, today announced that the U.S. Food and Drug Administration (FDA) has granted pediatric exclusivity for Nucynta® and Nucynta® ER (“the Nucynta Franchise”). In 2023, FDA granted New Patient Population exclusivity for Nucynta in pediatrics, extending the period of U.S. exclusivity from June 27

Revelation Biosciences, Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a clinical-stage life sciences company that is focused on harnessing the power of trained immunity for the prevention and treatment of disease, announced today that it has completed enrollment and dosing of its first in human Phase 1 clinical study (RVL-HV02). The study, which was conducted in Australia, evaluated escalating doses of intravenously administered Gemini and enrolled 40 healthy in

Alzheon, Inc., a clinical-stage biopharmaceutical company developing a broad portfolio of product candidates and diagnostic assays for patients suffering from Alzheimer’s disease (AD) and other neurodegenerative disorders, today announced that it has raised $100 million in Series E financing, led by Alerce Medical Technology Partners. Alzheon previously raised $50 million through a Series D financing round in 2022. “Alzheon has experienced tremendous progress in the past

Simulations Plus, Inc., a leading provider of modeling and simulation software and services for pharmaceutical safety and efficacy, today announced the acquisition of Pro-ficiency Holdings, Inc. and its subsidiaries (“Pro-ficiency”), a leader in providing simulation-enabled performance and intelligence solutions for clinical and commercial drug development. Simulations Plus acquired Pro-ficiency from QHP Capital, L.P. (management company for NovaQuest Private Equity) (“QHP C

CervoMed Inc., a clinical stage company focused on developing treatments for age-related neurologic disorders, today announced that it has completed enrollment in RewinD-LB, a Phase 2b trial evaluating neflamapimod in patients with dementia with Lewy bodies (DLB). “Drug development for the major dementias over the past decade has progressively focused on earlier stages of disease. In our phase 2a data with neflamapimod in patients with DLB, the treatment response in patients w

SciRhom GmbH, a biopharmaceutical company pioneering the development of first-in-class therapeutic antibodies, announced today the approval of a clinical trial application (CTA) by the Austrian regulatory authorities (BASG/AGES) for its development program SR-878. The upcoming clinical study aims to evaluate safety in healthy volunteers for the proprietary iRhom2-targeting monoclonal antibody SR-878 and provide initial evidence of clinical activity in a second part of the study. SciRhom expec

Olympus Corporation (Olympus), a global MedTech Company committed to making people’s lives healthier, safer and more fulfilling, today announced its strategic initiative to establish an R&D Offshore Development Center (ODC) in Hyderabad, India. This decision comes as a result of a strategic agreement with global technology company HCLTech, aimed at diversifying Olympus' innovation generation activities. Establishing this R&D ODC in Hyderabad is part of Olympus'

Arcus Biosciences, Inc., a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, today announced the completion of patient enrollment for STAR-221, a Phase 3 study in collaboration with Gilead Sciences, evaluating the combination of the Fc-silent anti-TIGIT antibody domvanalimab plus the anti-PD-1 monoclonal antibody zimberelimab and chemotherapy in patients with locally advanced unresectable or metast

Adcytherix SAS announced today its creation and the closing of a seed round of 30 million euros to develop new antibody conjugates (ADC) to treat pathologies in strong medical need, particularly cancer. The company was founded by Jack Elands and Pontifax Venture Capital, and counts Xavier Preville and Carsten Dehning as co-founders. The Adcytherix management team consists of Jack Elands (CEO), Carsten Dehning (CFO) and Xavier Preville (VP, head of research and preclinical developmen

BioCardia®, Inc., a company focused on cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announces that the Unites States Patent Office has granted Patent No: 11,986,611 titled “Radial and Transendocardial Delivery Catheter,” with a patent term that will expire in 2036.   The present invention relates to medical methods and systems suitable for substance delivery to the heart via a radial artery and for the